ARCT analyst estimates
Arcturus (ARCT) analyst ratings, the average price target and its range, and every firm's latest call.
ARCT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 24, 2026 | BTIG | Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG | $20.00 |
| Sep 2, 2026 | Roth Capital | Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital | $41.00 |
| Mar 4, 2026 | Piper Sandler | '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler | $25.00 |
| Jan 22, 2026 | Roth Capital | Arcturus Therapeutics initiated with a Buy at Roth Capital | $20.00 |
| Aug 22, 2025 | Leerink Partners | Arcturus Therapeutics price target lowered to $54 from $63 at Leerink | $54.00 |
| May 28, 2025 | Scotiabank | Arcturus Therapeutics initiated with an Outperform at Scotiabank | $32.00 |
| Mar 10, 2025 | BTIG | BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT) | $48.00 |
| Nov 11, 2024 | Canaccord Genuity | Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity | $74.00 |
| Aug 6, 2024 | Canaccord Genuity | Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord | $72.00 |
| Jul 2, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT) | $60.00 |
| May 31, 2024 | Piper Sandler | Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT) | $140.00 |
| May 10, 2024 | Canaccord Genuity | Arcturus Therapeutics price target lowered to $86 from $87 at Canaccord | $86.00 |
| Mar 19, 2024 | Laidlaw | Laidlaw Reiterates Buy Rating on Arcturus Therapeutics (ARCT) | $79.00 |
| Nov 2, 2022 | Barclays | Barclays Upgrades Arcturus Therapeutics (ARCT) to Equalweight | $25.00 |
| May 11, 2022 | Goldman Sachs | Goldman Sachs Maintains Sell on Arcturus Therapeutics, Lowers Price Target to $14 | $14.00 |
- 7 firms rate ARCT: 6 buy, 1 hold, 0 sell.
- The average price target is $30.50 from 2 analysts, from $20.00 to $41.00.
Updated 2026-11-02 17:52 UTC